Key figures

in CHF millions	2022	2021	2020	2019	2018
Net sales	725	497	445	525	534
Gross profit	294	161	190	227	222
Gross profit margin	40.6%	32.3%	42.8%	43.2%	41.7%
EBITDA Chemistry	19	20	9	9	11
EBITDA Paper	81	‑ 8	17	55	51
EBITDA Packaging	31	12	28	24	22
EBITDA Other/Consolidation	-	2	1	-	‑ 1
EBITDA	131	26	55	88	83
EBITDA margin	18.1%	5.2%	12.4%	16.8%	15.6%
EBIT	112	‑ 3₁	25	57	52
EBIT margin	15.5%	‑ 0.5%	5.5%	10.8%	9.7%
Net result	101	‑ 151	47	48	42
Return on equity ROE	28.5%	‑ 38.7%	10.3%	11.4%	10.5%
Cash flow₂	129	17	46	80	69
Cash flow from operating activities	98	16	55	61	64
Capital expenditures for fixed assets	34	25	19	23	24
Free cash flow	68	‑ 3	40	40	20
Total assets	666	560	704	703	800
Shareholders’ equity	400	310	472	441	407
Equity ratio	60.0%	55.4%	67.0%	62.8%	50.9%
Net cash	45	‑ 15	‑ 2	‑ 30	‑ 57
Net debt to EBITDA ratio	n.a.	0.6	0.0	0.3	0.7
Capital employed	344	319	468	477	470
Net operating profit after tax (NOPAT)	97	‑ 2	20	49	44
Return on capital employed (ROCE)	29.2%	‑ 0.6%	4.3%	10.3%	9.3%
Headcount (FTE)	1 181	1 104	1 098	1 086	1 081

1 before impairment

2 before change in non-financial net working capital

in CHF	2022	2021	2020	2019	2018
Share price as at 31 December	78.00	61.00	72.60	79.20	82.50
Price-earnings ratio as at 31 December	4.6	‑ 2.4	9.3	9.8	11.7
Earnings per share	16.83	‑ 25.26	7.82	8.06	7.05
Dividend per share	4.50₁	1.30	1.80	1.80	1.80
Dividend yield	5.8%	2.1%	2.5%	2.3%	2.2%
Market capitalization (in CHF millions)	468	366	436	475	495

1 Board of Directors’ proposal to Annual General Meeting of 14 March 2023